A novel liver targeted therapy for sarcopaenia in androgen deprived men with prostate cancer

The purpose of this research is to investigate the effectiveness of a new treatment to prevent the loss of muscle mass during ADT. This treatment is called liver-targeted testosterone therapy. Sarcopaenia is a scientific term describing the loss of mass and function. Suppression, blockade or removal of testosterone is a cornerstone of management of prostate cancer. ADT is effective treatment that improves survival. Because ADT is often prescribed for extended times, patients suffer from sarcopaenia, as a consequence of the absence of testosterone. As the 10-year disease survival exceeds 90% for most men, healthy survivorship becomes an important consideration.

The ensuing sarcopaenia leads to loss of muscle strength and easy fatigue, affecting quality of life. Up to 2.5% of lean mass is lost within the first 6 to 12 months, continuing at a lower rate thereafter. The annualised loss of lean body mass is about 10 times that occurring with ageing. Thus sarcopaenia prevention during ADT remains a major treatment frontier for prostate cancer. We apply a new approach to revolutionise the treatment of sarcopaenia based on our discovery that the liver plays an important role in mediating the stimulatory effects of testosterone on muscle growth. 



Prof Ken Ho PAH, TRI


2016 - 2018